MedTrace Logo

Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency

NCT01427725 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 579

Last updated 2022-06-13

Study results available
· View outcomes & findings →

Summary

This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients receiving the treatment with LipaCreon for a long term in order to evaluate the effective and safe use of LipaCreon.

Conditions

Interventions

DRUG

Lipacreon

This study was an observational study and no intervention was specified

Sponsors & Collaborators

  • Mylan Inc.

    lead INDUSTRY

Principal Investigators

  • Jun Kato, MD.,Ph.D. · Abbott Japan Co.,Ltd

Eligibility

Min Age
1 Year
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-01-31
Completion
2015-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01427725 on ClinicalTrials.gov